AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06188520
Drug: Camizestrant
RxNorm normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SERD
Trial: NCT06188520
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CDK4/6 inhibitor
Trial: NCT06188520
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6 inhibitor
Trial: NCT06188520
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CDK4/6 inhibitor
Trial: NCT06400472
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT06400472
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT06360354
Drug: AMG 193
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT06360354
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT06360354
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT05170204
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive oral alectinib twice daily with food.
Trial: NCT05170204
Drug: Entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral entrectinib once daily, with or without food.
Trial: NCT05170204
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV durvalumab every 4 weeks.
Trial: NCT05039619
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Trial: NCT05039619
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Trial: NCT05039619
Drug: Diphenhydramine hydrochloride (HCl)
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Trial: NCT05039619
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Trial: NCT05039619
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Trial: NCT05047263
Drug: Finerenone (BAY94-8862)
RxNorm normalized name: Finerenone
DrugBank: Finerenone (DB16165)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet, 10 mg or 20 mg, once daily (OD), oral
Trial: NCT06548139
Drug: Rabies Human Immunoglobulin (HRIG)
RxNorm normalized name: Rabies immunoglobulin (human)
DrugBank: Rabies immune globulin, human (DB11603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active ingredient: Rabid human immunoglobulin
Trial: NCT06500702
Drug: frexalimab
RxNorm normalized name: Frexalimab
DrugBank: Frexalimab (DB18926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: frexalimab treatment
Trial: NCT06500702
Drug: rilzabrutinib
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilzabrutinib treatment
Trial: NCT04649385
Drug: BGB-15025
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once or twice daily (QD or BID)
Trial: NCT04649385
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 200 mg intravenous (IV) infusion
Trial: NCT05629208
Drug: Edecesertib
RxNorm normalized name: Edecesertib
DrugBank: Edecesertib (DB18917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT05629208
Drug: Edecesertib Placebo
DrugBank: Edecesertib (DB18917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT06600711
Drug: Nitazoxanide
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mL suspension (100 mg), 2x/day for 3 days
Trial: NCT06666855
Drug: DE-117B Eye Drops
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational Product: 0.002% DE-117B Eye Drops
Trial: NCT06661122
Drug: Darolutamide (BAY1841788) + docetaxel + ADT
RxNorm normalized name: darolutamide
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Follow clinical practice/administration. ADT=androgen deprivation therapy.
Trial: NCT06586515
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06586515
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06586515
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06586515
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06586515
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06586515
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously.
Trial: NCT06666855
Drug: Latanoprost
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active Control: 0.005% Latanoprost Eye Drops
Trial: NCT06632405
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every three weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
Trial: NCT06632405
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab paclitaxel 100mg/m2 will be administered as an intravenous infusion every 4 weeks in d1,8,15until unacceptable toxic effects or disease progression or other termination criteria appeared.
Trial: NCT06632405
Drug: Levocetirizine Hydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg daily, start 3 days before the 1st administration
Trial: NCT05769777
Drug: Amlitelimab
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
Trial: NCT06507436
Drug: Herombopag tablets
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herombopag tablets; dose 1 or dose 2, for 5 days
Trial: NCT05141708
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020
Trial: NCT04750226
Drug: ABBV-951
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for continuous subcutaneous infusion (CSCI).
Trial: NCT06010758
Drug: Colgate Cavity Protection Toothpaste
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will brush twice daily for 1 timed minute with Colgate Cavity Protection toothpaste.
Trial: NCT04611958
Drug: ERCP with Bupivacaine infusion
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective cannulation of the pancreatic duct with ERCP scope will be performed. Any contrast dye used will be carefully aspirated and the duct will be flushed with saline as necessary to clear all residual dye. The canula will be taken to the tail of the pancreatic duct, and gradually withdrawn with slow infusion of the bupivacaine solution. Liposomal bupivacaine (13.3 mg/ml of Exparel) will be injected into the main pancreatic duct for a total of 5-10 ml (depending on the length of the pancreatic duct).~Immediately after the procedure, the patient will be monitored for any evidence of acute pancreatitis (worsening abdominal pain, with amylase or lipase x3 upper limit of normal). The patient will be questioned daily after the procedure for common side effects of bupivacaine including nausea, fever, change in taste, dizziness, weakness, palpitations and loss of taste or any other new or unusual symptom.
Trial: NCT05686746
Drug: Baricitinib 4 MG
RxNorm normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg oral daily
Trial: NCT05686746
Drug: Baricitinib 2 MG
RxNorm normalized name: baricitinib 2 MG
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg oral daily
Trial: NCT05686746
Drug: MMF
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral daily
Trial: NCT06178848
Drug: propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During induction, the propofol group initiates with a target-controlled infusion (TCI) of propofol, starting at an effect site concentration of 4.0 ng/ml. After intubation, it is adjusted to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Trial: NCT06178848
Drug: remimazolam group
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The remimazolam group begins with a continuous infusion of remimazolam at 6 mg/kg/hr, which is then adjusted to 1 mg/kg/hr after loss of consciousness to maintain an appropriate depth of anesthesia based on the EEG (psi target 40).
Trial: NCT05806515
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06090981
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of surfactant: 4ml/kg Type of surfactant: 4ml/kg
Trial: NCT05803863
Drug: Myatro XL
RxNorm normalized name: XL-888
DrugBank: XL-888 (DB12981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: myopia control with 0.05% atropine drops
Trial: NCT05547399
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally as a tablet or capsule
Trial: NCT04973683
Drug: AL101
RxNorm normalized name: Alpelisib
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06598787
Drug: BL-B01D1 for Injection
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06658964
Drug: Cohort 1: JMKX003142 and itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD
Trial: NCT06660940
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Lead-in period (2-4 weeks): Irbesartan 75-300mg/d, QD;~2. Treatment period (52 weeks): Irbesartan 75-300mg/d, QD
Trial: NCT06658652
Drug: Enlicitide decanoate
RxNorm normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04870671
Drug: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
Trial: NCT04707768
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral tablets
Trial: NCT06660017
Drug: Ketamine Topical
RxNorm normalized name: ketamine topical
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive ketamine oral rinse dispensed as 20mg/5ml 4 times a day in addition to receiving one of the following standard treatments; Magic Mouthwash, saliva substitute rinses, over-the-counter remedies including honey or salt and soda rinses, non-steroidal anti-inflammatory drugs (NSAIDS), or opioid medications.
Trial: NCT06659770
Drug: Zevorcabtagene Autoleucel
RxNorm normalized name: Zevorcabtagene autoleucel
DrugBank: Zevorcabtagene autoleucel (DB17266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zevorcabtagene Autoleucel is a novel fully human BCMA-targeting CAR-T therapy
Trial: NCT06600282
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmacokinetic study under fasting conditions
Trial: NCT04926831
Drug: capmatinib
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg and 200 mg tablets for oral administration
Trial: NCT06149481
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg infused via IV over 30 minutes every 28 days
Trial: NCT06149481
Drug: N-803
RxNorm normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ug/kg administered via subcutaneous injection to the abdomen every 28 days
Trial: NCT06149481
Drug: SX-682
RxNorm normalized name: SX-682
DrugBank: SX-682 (DB19210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg administered orally twice per day on days 6-26 of every cycle
Trial: NCT05319730
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Trial: NCT05319730
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
Trial: NCT05319730
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg oral administration every day.
Trial: NCT05319730
Drug: Antihistamine
RxNorm normalized name: Antihistamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered per product label.
Trial: NCT05319730
Drug: H2 Receptor Antagonist
RxNorm normalized name: Histamine H2 receptor antagonist
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered per product label.
Trial: NCT05319730
Drug: Dexamethasone (or equivalent)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered per product label.
Trial: NCT05319730
Drug: Steroid Mouthwash (dexamethasone or equivalent)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered per product label.
Trial: NCT06682728
Drug: Sacituzumab Govitecan (SG)
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT06682728
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT06690242
Drug: Etelcalcetide Hydrochloride
RxNorm normalized name: Etelcalcetide hydrochloride
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: the already-marketed therapeutic agents
Trial: NCT00049959
Drug: verteporfin PDT
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04234048
Drug: Fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts~Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts~Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort
Trial: NCT06795581
Drug: 18F-PF-06445974
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected IV followed by PET scanning
Trial: NCT05417594
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive temozolomide orally.
Trial: NCT05417594
Drug: Datopotamab Deruxtecan (Dato-DXd)
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Dato-DXd intravenously.
Trial: NCT05417594
Drug: Trastuzumab Deruxtecan (T-DXd)
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive T-DXd intravenously.
Trial: NCT06572982
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg Film coated tablets
Trial: NCT05952557
Drug: Camizestrant
RxNorm normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camizestrant. Experimental. Administered orally
Trial: NCT05952557
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen. Comparator. Administered orally
Trial: NCT05952557
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole. Comparator. Administered orally
Trial: NCT05952557
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole. Comparator. Administered orally
Trial: NCT05952557
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane. Comparator. Administered orally
Trial: NCT05952557
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemaciclib adjuvant treatment Administered orally
Trial: NCT05581004
Drug: RO7502175
RxNorm normalized name: RO7502175
DrugBank: RO7502175 (DB17502)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7502175 will be administered as per the schedules specified in the respective arms.
Trial: NCT05581004
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered as per the schedules specified in the respective arms.
Trial: NCT05581004
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered as per the schedules specified in the respective arms.
Trial: NCT04734418
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
Trial: NCT04851119
Drug: Tegavivint
RxNorm normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06481228
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BCL2 inhibitor
Trial: NCT06481228
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI